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 Establishing a diff erential diagnosis for an 
acute elevation in serum creatinine evokes 
considerable anxiety in both the physician 
and the patient. It is now fairly well estab-
lished that small changes in serum creati-
nine are associated with short- and 
long-term adverse events. 1,2 Consequently, 
determining whether the increase in serum 
creatinine represents structural damage or 
a reversible functional change takes on 
some urgency, as therapeutic strategies are 
somewhat diff erent. Th e available clinical 
data, information on the nature and timing 
of the event, the rapidity and duration of the 
changes, and the response to improved 
hemodynamics and hydration all contri-
bute to the diff erential diagnosis. However, 
the lack of any standardized criteria for 
‘ pre-renal ’ functional changes without 
structural damage in the kidney adds to the 
uncertainty in the decision. 3,4 Currently, 
the term  ‘ pre-renal failure ’ is widely accep-
ted to describe a reversible form of renal 
dysfunction and encompasses different 
conditions that vary considerably in the 
pathophysiology and course, including 
intravascular volume depletion, relative 
hypotension, compromised cardiac output, 
and hepatorenal syndrome. Embedded in 
this concept is that a pre-renal state is a 
dynamic process that begins with a revers-
ible condition, and can progress to an estab-
lished disease, acute tubular necrosis. To a 
large extent, pre-renal states represent acti-
vation of various compensatory pathways 
within the kidney that are activated in 
response to a precipitating event. 5 When 
there is an adequate renal reserve, these 
mechanisms are adequate in maintaining 
homeostasis. However, when these mecha-
nisms are compromised (for example, by 
prior kidney damage or drugs such as angi-
otensin-converting enzyme inhibitors 
or nonsteroidal anti-infl ammatory drugs), 
the response to an inciting event may be 
attenuated. 6 In clinical practice, diagnostic 
strategies have usually been based on 
demonstration of a fl uid-responsive change 
in renal function; however, the type and 
volume of fl uid required and the time for 
reversibility are not clearly designated. 1 
Furthermore, pre-renal states as a compli-
cation in patients with normal kidney-func-
tion reserve have not been distinguished 
from those in patients with a compromised 
renal reserve or a reduced level resulting 
from chronic kidney disease. It is particu-
larly diffi  cult to distinguish the coexistence 
of structural damage and a pre-renal condi-
tion ( Figure 1 ). Given these constraints, a 
biomarker confirming the presence of 
structural kidney change would be very 
valuable to determine the acuity and mag-
nitude of damage and defi ne the presence 
of a functional change. However, to be use-
ful clinically it would need to provide addi-
tional information beyond that obtained 
through clinical evaluation and standard 
laboratory measurements. 
 Several candidate biomarkers are now 
being evaluated for their utility in detect-
ing structural damage to the kidney and 
diff erentiating pre-renal states. Th e study 
by Singer  et al. 7 (this issue) provides sup-
port for neutrophil gelatinase-associated 
lipocalin (NGAL) as a marker of kidney 
damage to discriminate  ‘ pre-renal ’ from 
 ‘ intrinsic ’ acute kidney injury (AKI). 
Th ese investigators measured urine NGAL 
in 145 hospitalized patients with elevated 
serum creatinine values who met the 
RIFLE criteria for AKI (either a   >  50 % 
increase in serum creatinine concentra-
tion or a   >  25 % decrease in glomerular 
fi ltration rate compared with baseline). 
Samples were collected at enrollment and 
2 days later. Patients were followed 
through their hospital course to ascertain 
whether they met a composite outcome of 
death, dialysis, or progression of RIFLE 
class. Two clinicians reviewed the clinical 
data and determined whether the patients 
had  ‘ pre-renal ’ (22.1 % ) or intrinsic AKI 
(51.7 % ) or were unclassifi able (26.2 % ). 
Urine NGAL levels were evaluated in the 
context of this stratifi cation for their diag-
nostic accuracy and prognostic ability. 
Urine NGAL levels at thresholds greater 
than 104   g / l and less than 47   g / l identi-
fi ed patients who had intrinsic and pre-
renal AKI, respectively, with an overall 
area under the receiver operating charac-
teristic curve of 0.87 and a high specifi city 
and predictive value for meeting a com-
posite outcome when the levels were 
higher than 104   g / l. Higher NGAL levels 
were associated with a greater probability 
of reaching the composite outcome. Th ese 
data provide a foretaste of how biomark-
ers may be benefi cial in improving the 
diff erential diagnosis of AKI; however, 
several caveats need to be considered. 
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 For instance, the availability of N-
terminal brain natriuretic peptide (BNP) 
to diff erentiate heart failure from other 
causes of pulmonary congestion 8 is analo-
gous to the use of NGAL to diff erentiate 
pre-renal from intrinsic AKI. Both heart 
failure and AKI represent complex, 
heterogeneous sets of clinical conditions 
in which rapid, accurate diagnosis is vital, 
delayed therapy is associated with 
increased mortality and adverse out-
comes, and the therapeutic strategies are 
quite diff erent depending on the diagno-
sis. It is now well established that although 
natriuretic peptides have been useful in 
identifying patients with heart failure and 
have guided management, they have had 
limitations, and although low values may 
rule out heart failure, elevated values 
are subject to several confounders; for 
example, BNP levels are increased in renal 
dysfunction. Experience from cardiovas-
cular biomarkers is instructive in evaluat-
ing the proposed value of renal biomarkers 
in diff erential diagnosis of AKI. Morrow 
and de Lemos 9 have suggested that several 
criteria need to be met to establish the 
value of a biomarker to improve patient 
management ( Figure 1 ). First, the assay 
should be precise, accurate, and rapidly 
available to the clinician at a relatively low 
cost. Singer  et al. 7 used an automated 
ARCHITECT (Abbott Laboratories) tech-
nology platform for the NGAL assays, 
thereby standardizing the assay character-
istics. A key limitation in the fi eld of renal 
biomarkers is that, unlike for BNP for 
heart failure or troponin for acute coro-
nary syndrome, large-scale population-
based  ‘ normal ranges ’ of NGAL and other 
kidney biomarkers have yet to be estab-
lished. Published studies of NGAL show 
wide variation in levels, with non-para-
metric distributions and wide confi dence 
intervals that may reduce precision. 10 Th e 
availability of a standard platform for 
assays will certainly enhance the wider 
applications of these assays; however, 
there is an urgent need to develop stand-
ards for comparisons across patient 
cohorts. Point-of-care tests are now 
becoming available for NGAL and other 
biomarkers 3 and should facilitate the 
bedside application of these tests; however, 
aff ordability still needs to be determined. 
 Second, the biomarker must provide 
additional information that is not surmised 
from clinical evaluation. 9 In the study by 
Singer  et al. , 7 all enrolled patients had AKI; 
however, on adjudication by two clinicians, 
26.2 % of the patients were labeled as 
unclassifi able, as their clinical and labora-
tory measurements did not conform to 
pre-renal or AKI criteria. Th e  ‘ unclassifi a-
ble ’ patients had comorbidities and clinical 
and laboratory parameters similar to those 
of the other enrolled patients. While NGAL 
levels generally tracked the pre-renal and 
AKI groups, there was considerable overlap 
of NGAL values in the unclassifi ed group. 
NGAL did not result in any improvement 
in classifi cation based on the established 
thresholds. Th e incremental value of add-
ing NGAL to a creatinine-based logistic 
regression model only marginally improved 
the diagnostic accuracy for a composite 
outcome, from 68.3 % to 74.5 % . Th e inabil-
ity of NGAL to improve the net reclassifi ca-
tion of the unclassifi able patients, in whom 
it would have the most value, highlights 
several gaps in our knowledge. 11 
 The challenge in distinguishing pre-
renal from intrinsic renal failure is most 
acute when there is clinical uncertainty 
regarding the diagnosis. This usually 
stems from a lack of information on the 
nature, timing, and duration of the insult 
and information on the underlying level 
of kidney function prior to the event. 
In most studies, there has been a lack of 
consensus on what  ‘ reference ’ point should 
define the onset of AKI. In the study 
by Singer  et al. , 7 the  ‘ baseline ’ creatinine 
was determined by  “ review of the previous 
12 months of the medical record, or if 
unavailable, baseline serum creatinine was 
assumed from the hospital course. ” As 
discussed previously, 12 I would suggest 
distinguishing a  ‘ baseline ’ value to inform 
a person ’ s chronic kidney disease status 
and a  ‘ reference ’ creatinine to defi ne a start-
ing point for AKI diagnosis and staging. 
I believe this will standardize the approach 
and reduce misclassification in future 
studies. An additional limitation is the 
reliance on a single measurement of 
the biomarker. Although initial and 48-h 
values of urine NGAL were obtained, 
dynamic changes in biomarker levels were 
not formally evaluated. Recently, Swami-
nathan  et al. 13 have shown the value of 
changes in the pattern of serum creatinine 
in distinguishing progression of and 
recovery from AKI. Future studies should 
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 Figure 1  |  Pre-renal state is a dynamic process that begins with a reversible condition, and 
can progress to an established disease, acute tubular necrosis. To a large extent, pre-renal 
states represent activation of various compensatory pathways within the kidney that are activated 
in response to a precipitating event. When there is an adequate renal reserve, these mechanisms 
are adequate in maintaining homeostasis. However, when these mechanisms are compromised 
(for example, by prior kidney damage or drugs such as angiotensin-converting enzyme inhibitors 
or nonsteroidal anti-inflammatory drugs), the response to an inciting event may be attenuated. 
The ability of a biomarker to distinguish between a pre-renal state and structural damage will 
depend on where in the course it is applied. As this figure shows, different biomarkers may have 
different capabilities of defining pre-renal states depending on the nature and timing of the 
biomarker and the status of the kidney. Since pre-renal states can be superimposed and coexist 
with structural damage, in ideal situations, biomarkers A and B would detect reversible changes 
and differentiate them from damage.  The magnitude of biomarker change would reflect the 
response to therapeutic intervention. It is likely that a panel of biomarkers would be needed to 
achieve this level of differential diagnosis, particularly where damage is ongoing and a pre-renal 
condition is superimposed. CKD, chronic kidney disease. 
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determine the value of dynamic changes 
in NGAL levels to diff erentiate pre-renal 
and intrinsic AKI and could be valuable 
in defi ning the response to a corrective 
intervention such as fl uid resuscitation. 
 Finally, the Morrow and de Lemos 9 cri-
teria require that the absolute measured 
value should help in clinical decision mak-
ing. As an example, REDHOT (the Rapid 
Emergency Department Heart Failure 
Outpatient Trial) showed that BNP levels 
greater than 200 pg / ml in patients admit-
ted with congestive heart failure  were 
predictive of the 90-day combined event 
rate (congestive heart failure  visits and 
mortality). 14 Additional studies in larger 
cohorts will need to confi rm that the pro-
posed NGAL cutoff s of 47 and 104   g / ml 
are robust and predictive of the course for 
AKI. Determining the most effi  cient cut-
off s to establish thresholds for negative 
and positive predictive values requires 
adjudication of events and consideration 
of the clinical context wherein the bio-
markers are being measured. 11 Since pre-
renal states can occur independently of 
structural changes or concurrently with 
structural changes, thresholds may vary 
( Figure 1 ). For instance, NGAL values 
to distinguish pre-renal from intrinsic AKI 
may be very different in a patient with 
prior normal kidney function versus a 
patient suspected to have hepatorenal or 
cardiorenal syndrome, in whom the asso-
ciated comorbidities and underlying renal 
dysfunction would add more complexity. 
A combination of markers may be required 
in this situation for the best results. 
 Singer  et al. 7 have added one more piece 
to the puzzle of defi ning how we should 
best use biomarkers to manage patients 
with AKI. Th eir fi ndings highlight the need 
to develop clear defi nitions of pre-renal 
state, defi ning criteria, and the process for 
adjudication of events and use of multima-
rker combinations to improve discrimina-
tory ability. NGAL is a strong contender in 
the race for the  ‘ BNP of the kidney ’ ; how-
ever, the fi nish line is still a ways off . 
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 Th ere is a spate of interest in the role of 
microRNAs (miRNAs) in the pathogenesis 
of renal diseases. Th e miRNAs are regula-
tors of gene expression. They are short 
stretches of RNA (approximately 22 nucle-
otides long) that do not code for proteins. 
A double-stranded precursor of miRNA 
with a hairpin confi guration, called the pri-
miRNA, is transcribed by RNA polymerase 
II from a specifi c gene or from introns of a 
gene coding for protein 1 ( Figure 1 ). Pri-
miRNA is processed by an RNase type III 
endonuclease, Drosha, with the aid of a 
protein, DiGeorge syndrome critical region 
8 (DGCR8), into to an approximately 70-
nucleotide-long double-stranded form 
called the pre-miRNA. Th e pre-miRNA 
transport out of the nucleus is facilitated by 
exportin 5. In the cytoplasm, the pre-
miRNA binds to transactivation-responsive 
(TAR) RNA-binding protein, Argonaute 
(Ago) proteins, and Dicer, an RNA type III 
endonuclease, and is converted into an 
 The complex world of 
kidney microRNAs 
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 MicroRNAs are short noncoding RNAs that usually reduce translation of 
messenger RNAs. Changes in microRNA-192 (miR-192) are reported in 
states of renal fibrosis. New evidence supports a role for miR-192 and its 
target miR-200b / c in transforming growth factor-  1 regulation of its 
own expression and that of collagens in mesangial cells, with a possible 
role in diabetic nephropathy. As there is controversy on the role of these 
microRNAs in diabetic nephropathy, more work is needed. 
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